Genomic profiling is crucial in metastatic colorectal cancer (CRC) management: RAS and BRAF alterations govern prognosis and eligibility for targeted therapies. The expanding landscape of RAS directed ...

AI-driven genomic analysis could help researchers identify existing drugs that may be repurposed for subtype-specific breast ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” paradigm and enabling inhibitors that engage previously hidden pockets.

Researchers suggest targeting mTOR activity in aggressive cancers by blocking cholesterol sensing may represent a promising ...

Amplia Therapeutics is launching a new clinical trial of its protein inhibitor drug narmafotinib in ovarian cancer, partnering with research group ANZGOG.

Last month, Revolution Medicines’ RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. On the biotech’s heels are Immuneering, Actuate Therapeutics, Erasca and more, looking to improve ...